Scisparc Ltd (SPRC)

$0.77 +0.00 (0.13%)
Market Cap 411,000.00
Revenue (ttm) 1.31M
Net Income (ttm) -6.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -479.39%
Debt to Equity Ratio -30.38
Volume 691,000
Avg Vol 2,551,708
Day's Range N/A - N/A
Shares Out 535,000.00
Stochastic %K 15%
Beta 1.66
Analysts Strong Buy
Price Target $20.00

Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. It also sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufac...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 334 47180
Address:
Tower A, 2nd Floor 20 Raul Wallenberg Street, Tel Aviv, Israel
electroboy
electroboy Feb. 3 at 12:31 AM
$SPRC
0 · Reply
Stackdoe1
Stackdoe1 Feb. 2 at 2:55 PM
$SPRC $TOYO $FUSE $RPGL
0 · Reply
jamestocklover
jamestocklover Feb. 2 at 2:50 PM
$TLIH CHEAPEST LEVELS. LOADING ZONE. SOON $1+🔥🚀💯 $FUSE nice uptrend $DKI still top gainer $SXTC be careful $SPRC PATENT NEWS. MULTIBAGGER
0 · Reply
jamestocklover
jamestocklover Feb. 2 at 2:41 PM
$TLIH IS ABOUT TO EXPLODE. LOADING ZONE. SOLID UPTREND SOON.🔥🚀💯 $DKI be careful $SXTC reverse split $RPGL dilution $SPRC GREAT PATENT NEWS. MULTIBAGGER
0 · Reply
jamestocklover
jamestocklover Feb. 2 at 2:30 PM
$SPRC SOON $2+. GREAT PATENT NEWS🔥🚀💯 $TLIH UNDER ACCUMULATION. MULTIBAGGER🔥🚀💯 $DKI nice $SXTC reverse split game $FUSE 👀
0 · Reply
Wildjack54
Wildjack54 Feb. 2 at 2:18 PM
$SPRC promising money maker
0 · Reply
DARKP00L
DARKP00L Feb. 2 at 2:00 PM
$SPRC 08:28 on Feb. 02 2026 SciSparc Says NeuroThera Labs Granted U.S. Patent For Cannabinoid Technology To Overcome Antimicrobial Resistance. BZ NOTE: SciSparc Has 75% Controlling Interest In NeuroThera Labs #tradeideas
0 · Reply
Cup_of_Joe_Trader
Cup_of_Joe_Trader Feb. 2 at 1:38 PM
$SPRC Released PR this morning and low float. I think it has potential for 1+ if more volume comes in. We want .70-.75 to hold.
0 · Reply
MovingFast77
MovingFast77 Feb. 2 at 1:30 PM
$SPRC #shortsqueeze #lowfloat
0 · Reply
MrTicker
MrTicker Feb. 2 at 1:28 PM
$SPRC SciSparc Says NeuroThera Labs Granted U.S. Patent For Cannabinoid Technology To Overcome Antimicrobial Resistance. BZ NOTE: SciSparc Has 75% Controlling Interest In NeuroThera Labs BENZINGA 7:27 AM ET 2/2/2026
0 · Reply
Latest News on SPRC
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Feb 2, 2026, 8:24 AM EST - 1 day ago

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Feb 2, 2026, 8:00 AM EST - 1 day ago

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

Jan 26, 2026, 8:13 AM EST - 8 days ago

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

Jan 13, 2026, 6:55 AM EST - 21 days ago

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Jan 12, 2026, 4:02 PM EST - 21 days ago

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Neurothera Labs Announces Results of AGM

Jan 8, 2026, 6:00 PM EST - 25 days ago

Neurothera Labs Announces Results of AGM

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Dec 30, 2025, 8:17 AM EST - 5 weeks ago

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Dec 30, 2025, 8:00 AM EST - 5 weeks ago

Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Dec 2, 2025, 9:29 AM EST - 2 months ago

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Dec 2, 2025, 8:05 AM EST - 2 months ago

Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

Dec 1, 2025, 8:32 AM EST - 2 months ago

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

Nov 26, 2025, 7:38 AM EST - 2 months ago

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 20, 2025, 6:42 AM EST - 2 months ago

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 19, 2025, 8:30 AM EST - 2 months ago

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

CMND

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 24, 2025, 7:55 AM EDT - 3 months ago

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Oct 23, 2025, 4:03 PM EDT - 3 months ago

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Oct 23, 2025, 8:55 AM EDT - 3 months ago

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.

Oct 22, 2025, 3:30 PM EDT - 3 months ago

Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Oct 20, 2025, 7:41 AM EDT - 3 months ago

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 15, 2025, 7:05 AM EDT - 3 months ago

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

Oct 6, 2025, 6:40 AM EDT - 4 months ago

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Sep 29, 2025, 4:03 PM EDT - 4 months ago

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

SciSparc Stock Surges As It Launches Initiative To Advance Drug Discovery With Quantum Algorithms

Sep 25, 2025, 1:06 PM EDT - 4 months ago

SciSparc Stock Surges As It Launches Initiative To Advance Drug Discovery With Quantum Algorithms

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

Sep 25, 2025, 7:05 AM EDT - 4 months ago

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

Aug 28, 2025, 9:24 AM EDT - 5 months ago

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

Aug 28, 2025, 6:45 AM EDT - 5 months ago

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Aug 7, 2025, 7:32 AM EDT - 6 months ago

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

Jul 30, 2025, 4:34 PM EDT - 6 months ago

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Jul 30, 2025, 8:12 AM EDT - 6 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

Jul 22, 2025, 7:32 AM EDT - 7 months ago

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

SciSparc Announces 1-for-21 Reverse Share Split

Jun 24, 2025, 5:03 PM EDT - 7 months ago

SciSparc Announces 1-for-21 Reverse Share Split

SciSparc Announces Publication of Japanese Patent Application

May 27, 2025, 7:32 AM EDT - 9 months ago

SciSparc Announces Publication of Japanese Patent Application

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Apr 25, 2025, 7:59 AM EDT - 10 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

CMND

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

Mar 3, 2025, 8:25 AM EST - 1 year ago

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

Feb 27, 2025, 8:45 AM EST - 1 year ago

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

Feb 18, 2025, 7:17 AM EST - 1 year ago

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

Feb 4, 2025, 9:00 AM EST - 1 year ago

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Jan 15, 2025, 7:34 AM EST - 1 year ago

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

Jan 13, 2025, 8:41 AM EST - 1 year ago

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Jan 7, 2025, 7:25 AM EST - 1 year ago

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

Jan 6, 2025, 11:04 AM EST - 1 year ago

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Jan 6, 2025, 7:50 AM EST - 1 year ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

Dec 31, 2024, 9:24 AM EST - 1 year ago

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

S&P 500 Edges Lower, SciSparc Shares Surge

Dec 26, 2024, 2:36 PM EST - 1 year ago

S&P 500 Edges Lower, SciSparc Shares Surge

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

Dec 26, 2024, 6:46 AM EST - 1 year ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

Dec 16, 2024, 7:40 AM EST - 1 year ago

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

Sep 30, 2024, 9:25 AM EDT - 1 year ago

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

Sep 26, 2024, 9:05 AM EDT - 1 year ago

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 23, 2024, 8:17 AM EDT - 1 year ago

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 18, 2024, 4:09 PM EDT - 1 year ago

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

electroboy
electroboy Feb. 3 at 12:31 AM
$SPRC
0 · Reply
Stackdoe1
Stackdoe1 Feb. 2 at 2:55 PM
$SPRC $TOYO $FUSE $RPGL
0 · Reply
jamestocklover
jamestocklover Feb. 2 at 2:50 PM
$TLIH CHEAPEST LEVELS. LOADING ZONE. SOON $1+🔥🚀💯 $FUSE nice uptrend $DKI still top gainer $SXTC be careful $SPRC PATENT NEWS. MULTIBAGGER
0 · Reply
jamestocklover
jamestocklover Feb. 2 at 2:41 PM
$TLIH IS ABOUT TO EXPLODE. LOADING ZONE. SOLID UPTREND SOON.🔥🚀💯 $DKI be careful $SXTC reverse split $RPGL dilution $SPRC GREAT PATENT NEWS. MULTIBAGGER
0 · Reply
jamestocklover
jamestocklover Feb. 2 at 2:30 PM
$SPRC SOON $2+. GREAT PATENT NEWS🔥🚀💯 $TLIH UNDER ACCUMULATION. MULTIBAGGER🔥🚀💯 $DKI nice $SXTC reverse split game $FUSE 👀
0 · Reply
Wildjack54
Wildjack54 Feb. 2 at 2:18 PM
$SPRC promising money maker
0 · Reply
DARKP00L
DARKP00L Feb. 2 at 2:00 PM
$SPRC 08:28 on Feb. 02 2026 SciSparc Says NeuroThera Labs Granted U.S. Patent For Cannabinoid Technology To Overcome Antimicrobial Resistance. BZ NOTE: SciSparc Has 75% Controlling Interest In NeuroThera Labs #tradeideas
0 · Reply
Cup_of_Joe_Trader
Cup_of_Joe_Trader Feb. 2 at 1:38 PM
$SPRC Released PR this morning and low float. I think it has potential for 1+ if more volume comes in. We want .70-.75 to hold.
0 · Reply
MovingFast77
MovingFast77 Feb. 2 at 1:30 PM
$SPRC #shortsqueeze #lowfloat
0 · Reply
MrTicker
MrTicker Feb. 2 at 1:28 PM
$SPRC SciSparc Says NeuroThera Labs Granted U.S. Patent For Cannabinoid Technology To Overcome Antimicrobial Resistance. BZ NOTE: SciSparc Has 75% Controlling Interest In NeuroThera Labs BENZINGA 7:27 AM ET 2/2/2026
0 · Reply
MovingFast77
MovingFast77 Feb. 2 at 1:28 PM
$SPRC here we go getting while you can $1.50 today easy 100% gain
0 · Reply
Trader1141
Trader1141 Feb. 2 at 1:27 PM
$SPRC Patent? EZ short 🤣
1 · Reply
Stock_Catcher
Stock_Catcher Feb. 2 at 1:26 PM
$SPRC SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
0 · Reply
MrTicker
MrTicker Feb. 2 at 1:24 PM
$SPRC SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA GLOBENEWSWIRE 7:24 AM ET 2/2/2026
0 · Reply
AlertsAndNews
AlertsAndNews Feb. 2 at 1:24 PM
$SPRC headline just out here SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
0 · Reply
Stackdoe1
Stackdoe1 Feb. 1 at 2:02 AM
$SPRC Will this actually turn into revenue? and when?
0 · Reply
CometaMan
CometaMan Jan. 30 at 2:25 PM
$SPRC amazing! This piece of manure used to run wild from $11 to mid $20S, those were the days. Wouldn’t it be nice now to see a RS and see it run to the $70 s Just do it!
0 · Reply
looking4financialfreedom
looking4financialfreedom Jan. 30 at 1:16 AM
$SPRC Look at that spread!!! I hope I wake up to that!
0 · Reply
MovingFast77
MovingFast77 Jan. 29 at 9:26 PM
$SMX and $SPRC SPRC #lowfloat ready for #shortsqueeze SpRc very low float SPRC has a 1000% upside with It's recent patents
1 · Reply
MovingFast77
MovingFast77 Jan. 29 at 6:12 PM
$SPRC pump is coming
1 · Reply
looking4financialfreedom
looking4financialfreedom Jan. 29 at 3:11 PM
$SPRC CROOKS!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
0 · Reply
IzY
IzY Jan. 29 at 3:11 PM
$SPRC i remember when did was 9,00bux , so whats up
0 · Reply